secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0000950170-24-029342
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista reports Phase 3 KONFIDENT success for sebetralstat, CEO transition, $150M financing
--------------------------------------------------------------------------------

- Phase 3 KONFIDENT met all primary and key secondary endpoints; sebetralstat safety profile similar to placebo.
- CEO transition: Benjamin Palleiko appointed CEO, succeeding prior CEO as part of commercial preparation.
- Closed underwritten offering netting ~$150.1M from 7.0M shares and 3.5M pre-funded warrants at $15.25/share.
- Net loss $29.0M ($0.84/sh) for fiscal Q3 ended Jan 31, 2024, vs $21.3M ($0.75) YoY; cash $75.6M.
- NDA submission on track for H1 2024; UK MHRA granted Innovation Passport for sebetralstat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024029342/0000950170-24-029342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024029342/kalv-20240311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer